PTGS2 and adenoma: The ApcMin mouse model predicted the adenoma-regressing activity of the NSAID sulindac and the COX-2 inhibitor celecoxib (Boolbol et al, 1996; Jacoby et al, 2000) in familial adenomatous polyposis coli patients (Giardiello et al, 1993; Steinbach et al, 2000).